We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
-4%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.26B
AUM Growth
-$362M
Cap. Flow
-$5M
Cap. Flow %
-0.12%
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17

Top Buys

Rank Stock Value
1
PM icon
Philip Morris
PM
+$38.3M
2
AMZN icon
Amazon
AMZN
+$27.7M
3
PLTR icon
Palantir
PLTR
+$17.5M
4
HIMS icon
Hims & Hers Health
HIMS
+$13.7M
5
YUMC icon
Yum China
YUMC
+$13.2M

Top Sells

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$39.4M
2
NVDA icon
NVIDIA
NVDA
+$30.1M
3
META icon
Meta Platforms (Facebook)
META
+$14.9M
4
BEKE icon
KE Holdings
BEKE
+$14.1M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$11.2M

Sector Composition

Rank Sector Weight
1 Technology 42.45%
2 Consumer Discretionary 16.26%
3 Communication Services 14.17%
4 Healthcare 8.06%
5 Consumer Staples 5.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
626
DELISTED
CARGO Therapeutics
CRGX
$4.65K ﹤0.01%
1,142
+176
+18% +$1.18K
ACIU icon
627
AC Immune
ACIU
$241M
$4.59K ﹤0.01%
2,454
+377
+18% +$950
VYGR icon
628
Voyager Therapeutics
VYGR
$189M
$4.58K ﹤0.01%
1,355
+208
+18% +$972
TVGN icon
629
Tevogen Bio Holdings
TVGN
$28.4M
$4.54K ﹤0.01%
84
+10
+14% +$658
NGNE icon
630
Neurogene
NGNE
$670M
$4.31K ﹤0.01%
368
+56
+18% +$973
NMRA icon
631
Neumora Therapeutics
NMRA
$306M
$3.88K ﹤0.01%
3,883
+491
+14% +$841
THRD
632
DELISTED
Third Harmonic Bio
THRD
$3.88K ﹤0.01%
1,118
+172
+18% +$834
FDMT icon
633
4D Molecular Therapeutics
FDMT
$526M
$3.71K ﹤0.01%
1,147
+176
+18% +$829
SLDB icon
634
Solid Biosciences
SLDB
$836M
$3.67K ﹤0.01%
991
+152
+18% +$651
TNGX icon
635
Tango Therapeutics
TNGX
$4.49B
$3.65K ﹤0.01%
2,665
+410
+18% +$1.01K
CMPS
636
Compass Pathways
CMPS
$1.56B
$3.61K ﹤0.01%
1,261
+193
+18% +$741
LRMR icon
637
Larimar Therapeutics
LRMR
$398M
$3.4K ﹤0.01%
1,583
+243
+18% +$768
SLN
638
Silence Therapeutics
SLN
$549M
$3.29K ﹤0.01%
1,165
+178
+18% +$869
SCPH
639
DELISTED
scPharmaceuticals
SCPH
$3.27K ﹤0.01%
1,242
+191
+18% +$622
NKTX icon
640
Nkarta
NKTX
$154M
$3.22K ﹤0.01%
1,751
+269
+18% +$552
ALEC icon
641
Alector
ALEC
$180M
$2.99K ﹤0.01%
2,429
+284
+13% +$462
ENTA icon
642
Enanta Pharmaceuticals
ENTA
$378M
$2.9K ﹤0.01%
525
+80
+18% +$494
LXEO icon
643
Lexeo Therapeutics
LXEO
$342M
$2.85K ﹤0.01%
820
+126
+18% +$558
CCCC icon
644
C4 Therapeutics
CCCC
$405M
$2.8K ﹤0.01%
1,751
+269
+18% +$802
EDIT icon
645
Editas Medicine
EDIT
$413M
$2.45K ﹤0.01%
2,113
+283
+15% +$416
FATE icon
646
Fate Therapeutics
FATE
$293M
$2.16K ﹤0.01%
2,737
+346
+14% +$424
KYTX icon
647
Kyverna Therapeutics
KYTX
$455M
$2.06K ﹤0.01%
1,070
+164
+18% +$485
PLRX icon
648
Pliant Therapeutics
PLRX
$65.6M
$2.04K ﹤0.01%
1,509
+231
+18% +$1.4K
MGNX icon
649
MacroGenics
MGNX
$240M
$1.98K ﹤0.01%
1,557
+239
+18% +$624
CLYM
650
Climb Bio
CLYM
$692M
$1.97K ﹤0.01%
1,616
+204
+14% +$331
24 25
26
27 28

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q1 2025 Portfolio in Review

As of Q1 2025, GF Fund Management held 683 positions worth $4.26B, down 7.8% from $4.62B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q1 2025 filing shows 46 new, 475 increased, 93 reduced and 17 closed positions. Its largest new stake was Hims & Hers Health: 368,661 shares worth $10.9M. The largest sale was Pinduoduo, an estimated $39.4M.

By sector, the portfolio is most concentrated in Technology at 42% of assets, down from 45% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q1 2025 buy was Hims & Hers Health: 368,661 shares worth $10.9M.
  • GF Fund Management added most to Philip Morris in Q1 2025, an estimated $38.3M increase.
  • GF Fund Management's biggest Q1 2025 reduction was Pinduoduo, cutting an estimated $39.4M.
  • GF Fund Management fully exited Applied Optoelectronics in Q1 2025, selling an estimated $5.07M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.26B portfolio in Q1 2025.
  • GF Fund Management opened 46 new positions and closed 17 in Q1 2025.
  • GF Fund Management's portfolio value fell 7.8% quarter-over-quarter to $4.26B.

Based on GF Fund Management's 13F filing for Q1 2025, filed 29 Apr 2025.